As of 2024-12-15, the EV/EBITDA ratio of Allergy Therapeutics PLC (AGY.L) is -8.92. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. AGY.L's latest enterprise value is 296.61 mil GBP. AGY.L's TTM EBITDA according to its financial statements is -33.24 mil GBP. Dividing these 2 quantities gives us the above AGY.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.0x - 7.2x | 4.6x |
| Forward P/E multiples | 4.9x - 6.9x | 5.3x |
| Fair Price | (3.29) - (4.66) | (3.32) |
| Upside | -153.0% - -175.1% | -153.6% |
| Date | EV/EBITDA |
| 2024-12-11 | -8.78 |
| 2024-12-10 | -9.07 |
| 2024-12-09 | -9.04 |
| 2024-12-06 | -8.92 |
| 2024-12-05 | -8.46 |
| 2024-12-04 | -7.90 |
| 2024-12-03 | -7.47 |
| 2024-12-02 | -7.47 |
| 2024-11-29 | -7.61 |
| 2024-11-28 | -7.53 |
| 2024-11-27 | -7.61 |
| 2024-11-26 | -7.61 |
| 2024-11-25 | -7.18 |
| 2024-11-22 | -7.32 |
| 2024-11-21 | -7.47 |
| 2024-11-20 | -7.90 |
| 2024-11-19 | -7.88 |
| 2024-11-18 | -7.61 |
| 2024-11-15 | -7.93 |
| 2024-11-14 | -7.90 |
| 2024-11-13 | -7.79 |
| 2024-11-12 | -8.05 |
| 2024-11-11 | -7.96 |
| 2024-11-08 | -7.76 |
| 2024-11-07 | -8.05 |
| 2024-11-06 | -7.90 |
| 2024-11-05 | -7.79 |
| 2024-11-04 | -7.90 |
| 2024-11-01 | -7.90 |
| 2024-10-31 | -7.76 |
| 2024-10-30 | -7.18 |
| 2024-10-29 | -7.61 |
| 2024-10-28 | -7.47 |
| 2024-10-25 | -7.61 |
| 2024-10-24 | -7.18 |
| 2024-10-23 | -7.18 |
| 2024-10-22 | -7.00 |
| 2024-10-21 | -7.18 |
| 2024-10-18 | -7.00 |
| 2024-10-17 | -6.81 |
| 2024-10-16 | -7.18 |
| 2024-10-15 | -6.08 |
| 2024-10-14 | -6.08 |
| 2024-10-11 | -6.08 |
| 2024-10-10 | -6.08 |
| 2024-10-09 | -6.08 |
| 2024-10-08 | -6.45 |
| 2024-10-07 | -6.96 |
| 2024-10-04 | -6.96 |
| 2024-10-03 | -7.10 |